Photocure Announces Positive Allumera(TM) Trial Results For Delivering
Significant Skin Appearance Improvements

Oslo, Norway, 4 February, 2011 - Photocure (OSE: PHO), a Norwegian specialty
pharmaceutical company focused in dermatology and cancer, today announced
positive results from its consumer trial with Allumera(TM), a breakthrough
cosmetic treatment formulated to improve the skin's appearance.

The RevitAll study was performed with a standard cosmetic protocol and designed
to confirm if treatment with Allumera(TM) improves skin appearance, when
compared to exposure by light alone. The study also looked into longevity of
results.

This controlled, prospective study enrolled 120 women to receive three
treatments, four weeks apart. The total duration of the study was five months.
Half the study participants received Allumera(TM) plus light, while the
remaining received light alone (control group). Participants were monitored for
three months following the last treatment to evaluate which effects were long-
lasting. The study evaluations included both objective and subjective
assessments. The objective assessments included measurement of appearance of
pores, skin firmness/elasticity, skin tone (radiance/luminosity), skin surface
topography and tolerability.

At the five month evaluation, participants who received Allumera(TM) for one
hour followed by exposure to light, showed a significant 44% reduction in the
appearance of pores (p<0.001), when compared to baseline, and the difference
between the two groups was statistically significant (p=0.002). A statistically
significant improvement (p<0.0001) in skin firmness and suppleness was also
observed for the Allumera group when compared to the control group. A 35%
improvement in the appearance of skin tone (p<0.05) was also found, but this,
however, was not statistically significant when compared to the control group.

"The results from our RevitAll study provide a solid foundation for our efforts
to commercialize Allumera(TM)," said Kjetil Hestdal, M.D. Ph.D., President and
Chief Executive Officer of Photocure. "It is a significant milestone for our
Photocure Technology(TM) and provides validation for for our technology in
cosmetic dermatology aimed at improving the skin's appearance. The launch of
Allumera(TM) will be a major step forward in establishing Photocure's US
business."

In addition to the objective statistical measurements, Allumera(TM) demonstrated
significant subjective feedback from trial participants including confirmation
of:

·         Revitalized, younger-looking, clearer and more beautiful skin
·         Reduced appearance of crows feet, dark circles, fine lines and
wrinkles
·         Firmer appearance of skin
·         Improvement in the feeling of moisture, smoothness and overall skin
texture

"Allumera(TM) is an exciting, effective new option to achieve a radiant and
supple facial appearance, with minimal downtime," said Mitchel P. Goldman, MD,
Volunteer Clinical Professor of Dermatology at University of California, San
Diego. "Allumera(TM) will be a valuable new product filling a gap for our
patients looking to discreetly and non-invasively minimize the appearance of
wrinkles, dark circles and pores."

Photocure is on track to launch Allumera in the US during second quarter 2011.
###

For further information, please contact:

Photocure

President & CEO Kjetil Hestdal

Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Christian Fekete

Tel: + 47 916 42 938, Email: cf@photocure.no

Capital MS&L
Mary Clark, Justine Lamond and Hollie Vile
Tel: +44 (0)20 7307 5337, Email:Photocure@capitalmsl.com

###

About Allumera(TM)
Allumera(TM) is a topical cosmetic cream specially formulated to improve the
overall appearance of skin. When used with light, Allumera(TM) works with the
body's capabilities to visibly reduce many unwanted skin characteristics, such
as the appearance of fine lines, dark circles, crow's feet and enlarged pores.
Photocure's Allumera(TM) is a unique skincare formula applied by a healthcare
professional and has been found to improve the overall appearance of skin,
leaving a more radiant, firmer and healthier complexion.

About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic therapy. Listed on the Oslo
Stock Exchange (OSE: PHO), Photocure develops and sells pharmaceuticals and
medical devices for the photodynamic treatment and diagnosis of cancer and
selected dermatology indications. The company strives to solve unmet needs by
developing new and innovative solutions based on its patented Photocure
Technology(TM). Photocure markets and sells its own products in selected markets
and has developed strong partnerships with leading pharmaceutical companies on a
regional and global basis. Photocure's bladder cancer diagnostic product,
Hexvix® is approved in the European Union and the US. Setting new standards for
diagnosis and treatment of several different conditions, Photocure
Technology(TM) is very selective, targeting only diseased cells and preserving
healthy tissue. Photocure Technology(TM) is being tested for new products and
indications including acne, improving the appearance of skin (Allumera(TM)),
diagnosing colon cancer (Lumacan(TM) which is outlicensed to Salix
Pharmaceuticals) and the treatment of pre-malignant cervical lesions (Cevira®).

Photocure®, Cevira® and Hexvix® are registered trademarks of Photocure ASA.

Photocure, Inc. is the marketing and sales subsidiary of Photocure ASA in the
US. It is located in Princeton, NJ.

For more information about Photocure, visit our website at www.photocure.com

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)

[HUG#1485408]

Photocure ASA - Positive Allumera Trial Results